Profile data is unavailable for this security.
About the company
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
- Revenue in INR (TTM)6.37bn
- Net income in INR592.79m
- Incorporated1958
- Employees358.00
- LocationKopran LtdParijat House1076, Dr. E. Moses Road, Worli9917MUMBAI 400018IndiaIND
- Phone+91 2 243661111
- Fax+91 2 224950363
- Websitehttps://www.kopran.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jagsonpal Pharmaceuticals Ltd | 2.10bn | 203.13m | 10.85bn | 1.03k | 54.21 | -- | 47.90 | 5.17 | 7.57 | 7.57 | 78.03 | -- | -- | -- | -- | 2,048,663.00 | -- | 10.95 | -- | 13.29 | 56.41 | 58.13 | 9.67 | 9.21 | -- | 26.27 | -- | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
Bajaj Healthcare Ltd | 4.76bn | -133.27m | 11.95bn | 944.00 | -- | -- | 81.22 | 2.51 | -4.82 | -10.30 | 172.62 | -- | -- | -- | -- | 5,041,608.00 | -- | 7.67 | -- | 14.11 | 48.43 | 33.26 | -2.80 | 7.99 | -- | 1.74 | -- | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
Ngl Fine Chem Ltd | 3.58bn | 420.29m | 13.12bn | 390.00 | 31.22 | -- | 34.02 | 3.66 | 68.03 | 68.03 | 580.00 | -- | -- | -- | -- | 9,188,328.00 | -- | 15.06 | -- | 19.58 | 52.02 | 43.53 | 11.73 | 13.15 | -- | 26.59 | -- | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
Bliss GVS Pharma Ltd | 7.94bn | 814.66m | 13.64bn | 831.00 | 17.02 | -- | 11.73 | 1.72 | 7.63 | 7.63 | 74.93 | -- | -- | -- | -- | 9,559,162.00 | -- | 6.46 | -- | 8.22 | 51.81 | 43.91 | 11.24 | 9.92 | -- | -- | -- | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
Lincoln Pharmaceuticals Ltd | 5.92bn | 979.63m | 14.60bn | 1.70k | 14.90 | -- | 13.36 | 2.47 | 48.91 | 48.91 | 295.69 | -- | -- | -- | -- | 3,483,600.00 | -- | 13.95 | -- | 16.54 | 51.92 | 50.65 | 16.54 | 14.71 | -- | 60.93 | -- | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 14.67bn | 38.00 | 155.81 | 56.47 | 163.36 | 32.58 | 15.98 | 15.98 | 90.25 | 44.09 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
Kopran Ltd | 6.37bn | 592.79m | 15.59bn | 358.00 | 22.26 | -- | 21.42 | 2.45 | 14.53 | 14.53 | 150.01 | -- | -- | -- | -- | 17,794,040.00 | -- | 8.47 | -- | 12.23 | 36.03 | 32.93 | 9.31 | 8.89 | -- | 27.17 | -- | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
JG Chemicals Ltd | -100.00bn | -100.00bn | 16.18bn | 56.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14.90 | -- | -43.84 | -- | -- | -- |
Beta Drugs Ltd | 2.96bn | 364.37m | 16.34bn | 315.00 | 44.83 | 10.40 | 35.34 | 5.52 | 37.90 | 37.90 | 307.60 | 163.43 | 1.31 | 4.51 | 4.17 | -- | 16.10 | 15.10 | 23.91 | 22.23 | 38.73 | 39.77 | 12.32 | 12.38 | 1.51 | 17.81 | 0.0654 | -- | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
Zota Health Care Ltd | 1.98bn | -242.34m | 17.52bn | 445.00 | -- | -- | 3,752.02 | 8.84 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
Windlas Biotech Ltd | 6.61bn | 596.01m | 18.38bn | 1.15k | 30.83 | -- | 24.16 | 2.78 | 28.52 | 28.52 | 316.58 | -- | -- | -- | -- | 5,730,702.00 | -- | -- | -- | -- | 37.39 | -- | 9.01 | -- | -- | 48.16 | -- | -- | 22.97 | -- | 36.51 | -- | -- | -- |
Panacea Biotec Ltd | 5.46bn | -279.53m | 19.24bn | 1.15k | -- | -- | 253.27 | 3.53 | -4.58 | -4.58 | 89.84 | -- | -- | -- | -- | 4,761,763.00 | -- | 10.26 | -- | 16.53 | 60.24 | 50.27 | -5.20 | 24.87 | -- | -17.30 | -- | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
Sigachi Industries Ltd | 4.10bn | 594.65m | 19.48bn | 991.00 | 36.44 | -- | 27.39 | 4.75 | 1.60 | 1.60 | 10.97 | -- | -- | -- | -- | 4,136,886.00 | -- | 14.77 | -- | 19.57 | 52.33 | 50.30 | 14.43 | 14.92 | -- | 7.19 | -- | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
Hester Biosciences Ltd | 2.99bn | 193.56m | 20.69bn | 642.00 | 104.55 | -- | 54.66 | 6.92 | 23.26 | 23.26 | 350.03 | -- | -- | -- | -- | 4,656,698.00 | -- | 6.15 | -- | 7.69 | 71.52 | 66.64 | 7.34 | 12.83 | -- | 2.26 | -- | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
Holder | Shares | % Held |
---|---|---|
Dimensional Fund Advisors LPas of 05 Sep 2024 | 80.47k | 0.17% |
American Century Investment Management, Inc.as of 05 Sep 2024 | 46.65k | 0.10% |
Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 4.89k | 0.01% |
Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 2024 | 375.00 | 0.00% |
DFA Australia Ltd.as of 31 Jul 2024 | 199.00 | 0.00% |